| For: | Li H, Fu ZY, Arslan ME, Cho D, Lee H. Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Exp Med 2021; 11(6): 79-92 [PMID: 36246150 DOI: 10.5493/wjem.v11.i6.79] |
|---|---|
| URL: | https://www.wjgnet.com/2220-315X/full/v11/i6/79.htm |
| Number | Citing Articles |
| 1 |
Lukas M. Braun, Yunjie Lu, Robert Zeiser. Clinical perspective and treatment of immune-related colitis after cancer immunotherapy. Trends in Cancer 2025; 11(11) doi: 10.1016/j.trecan.2025.07.005
|
| 2 |
Saeed Zivari Lashkajani, Yasaman Sadat Azad, Mohammad Taha Nami, Ali Darzi, Mahla shokouhfar, Sina Naddaf faizabadi, Maryam Diansaei, Komeil Aghazadeh-Habashi, Zahra Azimzadeh Tabrizi, Ahmad Ghorbani Vanan. Neurologic complications of immune checkpoint inhibitors: A comprehensive review. Biomedicine & Pharmacotherapy 2025; 192 doi: 10.1016/j.biopha.2025.118669
|
| 3 |
O. Gómez Escudero. Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologist. Revista de Gastroenterología de México (English Edition) 2024; 89(1) doi: 10.1016/j.rgmxen.2023.11.001
|
| 4 |
Manasa Ginjupalli, Jayalekshmi Jayakumar, Praneeth Bandaru, Vikash Kumar, Arnold Forlemu, Giovannie Isaac Coss, Denzil Etienne, Madhavi Reddy.
Pseudomembranous Colitis: Unveiling an Infrequent Culprit Beyond
Clostridium difficile
—A Case Report
. Journal of Investigative Medicine High Impact Case Reports 2025; 13 doi: 10.1177/23247096251347401
|
| 5 |
Sara Kiparizoska, Megan E. Murphy, Mark C. Mattar. Check this out: treatment paradigms in immune-checkpoint inhibitor colitis. Current Opinion in Gastroenterology 2023; 39(1) doi: 10.1097/MOG.0000000000000892
|
| 6 |
Hao Wen, Yange Qi, Jianbo Song, Xia Yan. Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1823949
|
| 7 |
Andreja Ocepek. Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases. Radiology and Oncology 2024; 58(2) doi: 10.2478/raon-2024-0022
|
| 8 |
Aditi Kumar, Hazem Alnatour, Gabriel Imbianozor, Sathiya Devi, Manel Mangalika, Philip Harvey. Checkpoint inhibitor colitis: a gastroenterologists’ perspective. Frontline Gastroenterology 2025; 16(5) doi: 10.1136/flgastro-2024-102905
|
| 9 |
Baixue Wu, Anqi Zhao, Wenlu Chen, Yuying Zhou, Wenbo Zhang, Yiwen Zhang, Qing Hou, Ningning Yao, Shuangping Zhang, Jianchun Duan, Ning Li, Jianzhong Cao. Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics. Frontiers in Microbiology 2025; 16 doi: 10.3389/fmicb.2025.1689735
|
| 10 |
Cristina Polo Cuadro, Pilar Corsino Roche, Marta Gascón Ruiz, Santiago García López, Carmen Yagüe Caballero, Ana Royo Esteban, Laura Almenara Michelena, Diego Casas Deza. Immune-Mediated Colitis in the Era of Immune Checkpoint Inhibition: From Mechanisms to Clinical Management. Gastroenterology Insights 2026; 17(1) doi: 10.3390/gastroent17010020
|
| 11 |
Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. International Journal of Molecular Sciences 2023; 24(14) doi: 10.3390/ijms241411504
|
| 12 |
Razan Aburumman, Saqr Alsakarneh, Rok Seon Choung, Joseph A. Murray, Adam C. Bledsoe. Risk of Coeliac Disease After Immune Checkpoint Inhibitor Exposure in Patients With Cancer. Alimentary Pharmacology & Therapeutics 2026; doi: 10.1111/apt.70968
|
| 13 |
Marianne Zoghbi, Kathryn J. Burk, Elio Haroun, Maria Saade, Maria Teresa Cruz Carreras. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview. Supportive Care in Cancer 2024; 32(10) doi: 10.1007/s00520-024-08889-2
|
| 14 |
Masashi Kono, Yoriaki Komeda, Hisato Kawakami, Satoru Hagiwara, George Tribonias, Kohei Handa, Shunsuke Omoto, Mamoru Takenaka, Hiroshi Kashida, Naoko Tsuji, Masatoshi Kudo. JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA‐4 and PD‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report. Cancer Reports 2024; 7(10) doi: 10.1002/cnr2.70032
|
| 15 |
Ihsan Baroudi, Ibrahim Abukhiran, Reetesh Pai, Akila Mansour. Histopathologic Features of Chimeric Antigen Receptor (CAR) T-cell Therapy-associated Gastrointestinal Mucosal Injury. American Journal of Surgical Pathology 2026; 50(7) doi: 10.1097/PAS.0000000000002544
|
| 16 |
O. Gómez-Escudero. Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogo. Revista de Gastroenterología de México 2024; 89(1) doi: 10.1016/j.rgmx.2023.11.001
|
| 17 |
Casey Fazer-Posorske, Lisa Kottschade, Anna Schwecke. The Basics of Cancer Immunotherapy. 2024; doi: 10.1007/978-3-031-59475-5_14
|
| 18 |
Skaistė Astašauskaitė, Rita Kupčinskaitė-Noreikienė, Inga Zaborienė, Rūta Vaičiūnienė, Tomas Vanagas, Darius Pranys, Lina Poškienė, Elona Juozaitytė. Multiorgan Toxicity from Dual Checkpoint Inhibitor Therapy, Resulting in a Complete Response—A Case Report. Medicina 2024; 60(7) doi: 10.3390/medicina60071129
|
| 19 |
Masaya Iwamuro, Takehiro Tanaka, Shunsuke Kagawa, Shoko Inoo, Motoyuki Otsuka. Collagenous Colitis in a Patient With Gastric Cancer Who Underwent Chemotherapy. Cureus 2023; doi: 10.7759/cureus.39466
|
| 20 |
Angelo Del Gaudio, Federica Di Vincenzo, Valentina Petito, Maria Cristina Giustiniani, Antonio Gasbarrini, Franco Scaldaferri, Loris Riccardo Lopetuso. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach. Inflammatory Bowel Diseases 2024; 30(6) doi: 10.1093/ibd/izad229
|
| 21 |
Zeljka Belosic Halle, Vedran Tomasic, Alen Biscanin, Petra Cacic, Ivona Saric, Sanda Mustapic, Josip Stojic, Kresimir Luetic, Dinko Bekic, Matej Paic, Domagoj Micetic, Irena Krznaric Zrnic, Ivna Olic, Melanija Razov Radas, Iva Skocilic, Marin Golčic, Laura Rados, Jasna Radic, Juraj Prejac, Ivana Mikolasevic. Immune-Mediated Colitis Induced by Immune Checkpoint Inhibitors: Pathophysiology, Clinical Management, and the Emerging Role of Fecal Microbiota Transplantation. Biomedicines 2026; 14(3) doi: 10.3390/biomedicines14030683
|
| 22 |
Fady Daniel, Tasnim Diab, Jad Bou Khalil, Nour El Akach, Mounir Barake, Maria El Tannir, Ali Chaitou, Hazem I. Assi. Identifying Patients at Risk for Immune Checkpoint Inhibitor-Induced Colitis: Evidence From a Real-World Oncology Cohort. Journal of Immunotherapy 2026; doi: 10.1097/CJI.0000000000000615
|
| 23 |
Marina Markovic, Danijela Niciforovic, Violeta Mladenovic, Dragica Pavlovic, Dragana Papic, Katarina Milojevic, Dalibor Jovanovic, Marija Spasojevic, Rade Milic. Immune-related adverse events—pembrolizumab-induced colitis—the importance of early diagnosis and treatment: A case report and review of the literature. International Journal of Immunopathology and Pharmacology 2025; 39 doi: 10.1177/03946320251326699
|
| 24 |
Antonietta Gerarda Gravina, Raffaele Pellegrino, Alfonso Esposito, Marina Cipullo, Mario Romeo, Giovanna Palladino, Patrizia Iodice, Alessandro Federico, Teresa Troiani. The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review. Cancers 2024; 16(3) doi: 10.3390/cancers16030611
|
| 25 |
Naimah Turner, Synat Keam, Noha Abdel-Wahab, Jocelynn Colunga-Minutti, Caroline A. Trejo, Fernanda G. Kugeratski, Mauro Di Pilato, Juan M. Sevillano Gutierrez, Cara Haymaker, Shabnam Shalapour, Adi Diab, Roza Nurieva. B cell-guided inflammatory cascade perpetuates ICI-mediated colitis. Cell Reports 2026; 45(9) doi: 10.1016/j.celrep.2026.117969
|
| 26 |
Qianjie Xu, Xiaosheng Li, Yuliang Yuan, Guangzhong Liang, Zuhai Hu, Wei Zhang, Ying Wang, Haike Lei. Development and validation of a nomogram for predicting immune-mediated colitis in lung cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study in China. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1510053
|